We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Antifibrotic Therapy
MedXY News
EnglishTag

Antifibrotic Therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model
newspirfenidoneGlottic Stenosis

Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model

By MedXY|Sep 17, 2026

This study investigates the efficacy of topical and systemic pirfenidone in reducing glottic stenosis induced by bleomycin in rats, demonstrating both routes reduce macroscopic stenosis, with systemic administration showing significant anti

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial
newsAntifibrotic Therapypirfenidone

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial

By MedXY|Nov 11, 2025

A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
Clinical UpdatesAntifibrotic TherapyBexotegrast

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY|Oct 8, 2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities